Mystic Pharmaceuticals Unveils Next Generation of Patient-Centric Sublingual Delivery Devices
Mystic Pharmaceuticals, Inc. recently announced the availability of its Javelin Sublingual drug delivery devices. Javelin Sublingual dispensers utilized Mystic’s VersiDoser and VRx2 platform technology, and are offered in mono-dose and multi-dose configurations. Sublingual and buccal delivery provides non-invasive delivery of drugs, peptides, proteins, and enzymes through mucosal surfaces in the oral cavity. This route avoids first- pass metabolism, provides rapid systemic uptake into the body, and can be self-administered by the patient. Applications include the delivery of therapeutics for pain, cardiovascular, allergy, seizure, sedation, emesis, hormones, diabetes, and vaccines.
Based on Mystic’s VersiDoser and VRx2 delivery technology, Javelin Sublingual dispensers provide precise dose delivery for liquid, powder, and reconstituted powder medications. All Javelin dispensers incorporate patient-centric ergonomic design features, such as side actuation, no priming and contoured surfaces to facilitate ease of use, comfort, and safety for the patient.
Each Javelin dispenser is customized to the pharma manufacturer’s Target Product Profile and technical specifications through Mystic’s product integration process. Utilizing the VersiDoser or VRx2 Delivery Platform technology, Mystic can cost effectively provide an optimized commercial product that delivers value for both the patient and the pharmaceutical manufacturer. This approach eliminates the compromises that often arise with commodity off-the-shelf dispensers.
Mystic will produce and fill Javelin Sublingual dispensers at its Austin, TX, manufacturing facility and internationally through its strategic manufacturing partners. For more information, please visit www.mysticpharmaceuticals.com
Total Page Views: 870
